Jeff Leiden (L) and Samarth Kulkarni
Vertex pays CRISPR $900M to take control of sickle cell partnership, betting they can beat bluebird -- and renewing analysts' skepticism
When Vertex chairman Jeffrey Leiden and CRISPR Therapeutics CEO Samarth Kulkarni got on the call for the first meeting of the year, the tenor was …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
